Advertisement

Topics

Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

16:15 EDT 16 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Factor XIa inhibitor moving into Phase 2 Trials for Secondary Stroke Prevention Bristol-Myers Squibb to receive upfront payment and companies to share development and commercialization costs, and glob...

Other Sources for this Article

Bristol-Myers Squibb
Media:
Lisa McCormick Lavery, 609-252-7602
lisa.mccormicklavery@bms.com
or
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
Investors:
Tim Power, 609-252-7509
timothy.power@bms.com
or
Bill Szablewski, 609-252-5894
william.szablewski@bms.com

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...